Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)

Phase 3 Unknown 50 enrolled Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

NaSingle-groupOpen-labelPrevention

Summary

Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac-M for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of 12-17 years old volunteers.

Timeline

Start: 2023-10
Primary completion: 2024-12
Completion: 2024-12

Publications

Shuliakova IV, Grousova DM, Iliukhina AA, Dzharullaeva AS, Lubenets NL, Ordzhonikidze MK, Izhaeva FM, Erokhova AS, Zorkov ID, Azizyan VV, Boeva ZD, Reshetnikov DA, Ermolova IA, Lega VA, Kovyrshina AV, Bukhtin KM, Romanova LP, Alekseeva EI, Borzakova SN, Rachina SA, Rusanova MG, Ozharovskaia TA, Popova O, Zrelkin DI, Zubkova OV, Tukhvatulin AI, Tukhvatulina NM, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Karpov AP, Semikhin AS, Pochtovyi AA, Naroditskiy BS, Gushchin VA, Gintsburg AL, Logunov DY. Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents. Front Immunol. 2026 Mar 26;17:1736771. doi: 10.3389/fimmu.2026.1736771. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GamCovidVac-M	Vaccine	—	Intramuscular

Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)

Summary

Timeline

Publications

Drugs

Indications